Tag: STEMI

1. Revascularization guided by fractional flow reserve (FFR) was shown not to have significant benefit compared to angiography for patients with ST segment-elevated myocardial infarction. 2. The wide confidence intervals for the estimate of treatment effect were unable to conclusively interpret the study’s findings. Evidence Rating Level: 1 (Excellent) Study Rundown: Percutaneous...
1. Patients without standard modifiable cardiovascular risk factors (SMuRFs) had a significantly higher all-cause mortality at 30 days after first presentation of STEMI. 2. Patients without SMuRFs were significantly less likely to receive statins, ACEIs, ARBs, or beta-blockers at discharge.  Evidence Rating Level: 2 (Good) Study Rundown: Standard modifiable cardiovascular risk factors...
1. Low BMI, Killip class 3/4, history of previous MI, use of mechanical support, and flow worsening were shown to be significantly associated with major adverse cardiac events (MACE) in patients with an ST-elevation myocardial infarction (STEMI) who have achieved a door-to-balloon time (DTBT) under 90 minutes. 2. Radial access...
1. The proportion of out of hospital cardiac arrests (OHCAs) within all acute myocardial infarction (AMI) hospital admissions was higher at the start of the COVID-19 pandemic compared to before, by a difference of 2.0%. 2. The in-hospital mortality rate for OHCAs during COVID-19 was higher than before, by a...
1. There is no significant difference in 30-day all-cause mortality between radial and femoral access for percutaneous coronary intervention (PCI) following ST-segment elevation myocardial infarction (STEMI). Evidence Rating Level: 1 (Excellent) Primary percutaneous coronary intervention (PCI) is the standard of care for achieving reperfusion in patients with ST-segment elevation myocardial infarction (STEMI)....
1. There is no significant difference in 30-day all-cause mortality between radial and femoral access for percutaneous coronary intervention (PCI) following ST-segment elevation myocardial infarction (STEMI). Evidence Rating Level: 1 (Excellent) Primary percutaneous coronary intervention (PCI) is the standard of care for achieving reperfusion in patients with ST-segment elevation myocardial infarction (STEMI)....
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab. Evidence Rating Level:...
1. In patients with STEMI and multivessel coronary artery disease, those randomized to the complete revascularization group experienced lower rates of cardiovascular death or myocardial infarction (MI) at 3 years compared to patients who were randomized to the culprit-lesion-only percutaneous coronary intervention group. 2. Both groups experienced similar rates of...
1. Patients with obesity undergoing percutaneous coronary intervention are typically younger with more cardiovascular risk factors, but may be less likely to experience procedural complications, short-term and long-term adverse outcomes, with the exception of patients considered extremely obese Evidence Rating Level: 2 (Good) It has been well established that obesity is...
1. In patients with STEMI and multivessel coronary artery disease, those randomized to the complete revascularization group experienced lower rates of cardiovascular death or myocardial infarction (MI) at 3 years compared to patients who were randomized to the culprit-lesion-only percutaneous coronary intervention group. 2. Both groups experienced similar rates of...